Plain-English translation of NCT06931652 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called , combined with two other drugs you may have heard of (rituximab and lenalidomide), to treat primary CNS lymphoma — a type of blood cancer in the brain — that has come back or stopped responding to previous treatment. The research team believes that adding this medication to the existing combination might help more patients recover and stay in remission longer.
Brain lymphoma is more likely to come back than similar lymphomas elsewhere in the body, and when it does return, treatment options are limited and outcomes remain poor. This trial exists to see whether the new treatment can improve survival and quality of life for patients whose cancer has already fought back against standard therapy.
You likely qualify if…
You likely don't qualify if…
You will receive induction treatment over 8 cycles (about 8 weeks), during which you'll take lenalidomide as a daily capsule, receive rituximab infusions, and receive the new medication . After that, you'll enter a maintenance phase lasting one year, taking only lenalidomide daily. You'll need regular blood tests and brain MRI scans to monitor how well the treatment is working and watch for side effects. In total, you'll be actively on treatment for approximately 14 months.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
France